Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


New Novartis thin-strip OTCs?

This article was originally published in The Tan Sheet

Executive Summary

Novartis and Adhesive Research's ARx division are expanding their work on developing Thin Strip offerings and have broken ground on a new facility that will be used to manufacture products employing the technology, the firms announce May 19. ARx Division already supports six thin film products, including Triaminic Thin Strips and Theraflu Thin Strips, both introduced by Novartis (1"The Tan Sheet" April 26, 2004, p. 13). ARx is the exclusive developer and supplier of active films for Novartis, and plans to launch 20 new products over the next three years. The firm is also developing a 25,000 square-foot facility, to be located on the ARx campus in Glen Rock, Penn. Novartis' launch of its thin strip products is "just the beginning of a relationship that will benefit from this new state-of-the-art facility"...

You may also be interested in...

Novartis Expects Thin Strips Technology To Drive OTC Cough/Cold Sales

Novartis Consumer Health is gearing up to launch new cough/cold products using a Thin Strips dosage form this summer

QUOTED. 13 December 2019. Todd Garner

ConMed's CFO Todd Garner told delegates at the Jefferies Healthcare conference that the company's orthopedic franchise is focused on its pipeline and meeting customer's needs.  See what the CFO said about it here.

Sarepta Scores Another Remarkable Approval With Vyondys 53 For Duchenne

Formal dispute resolution was key element in four-month turnaround from rejection by US FDA to approval for golodirsen, the second Sarepta DMD drug to clear the agency after appearing to have minimal prospects.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts